Skip to main content

Volume 7 Supplement 3

B cell targeted therapy: a new approach to the treatment of rheumatoid arthritis


Edited by Larry Moreland

Supported by an educational grant from Genentech, Inc.

  1. Until the pathophysiology/etiology of rheumatoid arthritis (RA) is better understood, treatment strategies must focus on disease management. Early diagnosis and treatment with disease-modifying antirheumatic d...

    Authors: Larry Moreland
    Citation: Arthritis Research & Therapy 2005 7(Suppl 3):S2
  2. In rheumatoid arthritis, T cells, B cells, macrophages, and dendritic cells invade the synovial membranes, establishing complex microstructures that promote inflammatory/tissue destructive lesions. B cell invo...

    Authors: Cornelia M Weyand, Thorsten M Seyler and Jörg J Goronzy
    Citation: Arthritis Research & Therapy 2005 7(Suppl 3):S9
  3. Although the precise pathogenesis of rheumatoid arthritis (RA) remains unclear, many cell populations, including monocytes, macrophages, endothelial cells, fibroblasts and B cells, participate in the inflammat...

    Authors: Edward Keystone
    Citation: Arthritis Research & Therapy 2005 7(Suppl 3):S13
  4. A substantial body of data supports use of rituximab as first-line and maintenance therapy for the treatment of indolent non-Hodgkin's lymphoma. With 7 years of postmarketing surveillance experience and more t...

    Authors: Ann Mohrbacher
    Citation: Arthritis Research & Therapy 2005 7(Suppl 3):S19

Annual Journal Metrics

  • 2022 Citation Impact
    4.9 - 2-year Impact Factor
    5.7 - 5-year Impact Factor
    1.501 - SNIP (Source Normalized Impact per Paper)
    1.592 - SJR (SCImago Journal Rank)

    2022 Speed
    7 days submission to first editorial decision for all manuscripts (Median)
    149 days submission to accept (Median)

    2022 Usage 
    17,226 Altmetric mentions